Actinium Pharmaceuticals awarded CEO Seth Sandesh 1,780,874 shares at $0 per share across two transactions on September 2. Afterward, Sandesh owned 1,965,355 shares and 1,130,400 derivative securities, giving investors the reported post-transaction ownership figures for the chief executive.
Key Highlights
- Seth Sandesh held 1,965,355 Actinium Pharmaceuticals shares after the transactions.
- Sandesh also owned 1,130,400 derivative securities following the award.
- Both share transactions carried SEC transaction code A.
Actinium Pharmaceuticals, Inc. (AMEX: ATNM) awarded CEO Seth Sandesh 1,780,874 shares at $0 per share on September 2. The shares were awarded through two transactions, and Sandesh’s reported share ownership afterward was 1,965,355 shares.
Derivative Securities Were Reported Separately
Both share transactions used SEC transaction code A. On the same date, Sandesh was awarded 1,130,400 derivative securities in a transaction carrying the same code. His post-transaction ownership of derivative securities was 1,130,400. The filing reported the $0-per-share price for the 1,780,874 shares and separately reported the derivative securities. Sandesh is identified as Actinium Pharmaceuticals’ chief executive officer.
FAQs
Q: How many shares did Actinium Pharmaceuticals CEO Seth Sandesh receive?
A: Seth Sandesh was awarded 1,780,874 Actinium Pharmaceuticals shares at $0 per share across two transactions dated September 2. His post-transaction ownership was 1,965,355 shares.
Q: What were Seth Sandesh’s post-transaction holdings?
A: Following the transactions, Seth Sandesh’s reported ownership was 1,965,355 Actinium Pharmaceuticals shares. His post-transaction ownership of derivative securities was reported separately as 1,130,400.
Q: How many derivative securities does Seth Sandesh own?
A: Seth Sandesh held 1,130,400 derivative securities after the September 2 transactions. The filing separately reported 1,965,355 shares owned after the share transactions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.